Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics, but not necessarily in the ways people might expect.
Personalized cancer therapy, for example, seems to be losing ground to other therapies simply because of logistics and finances. Speed of manufacturing and the cost of getting the therapy to the patient are the challenges, William Ho, CEO ofIn8bio, said during a live panel at Biotech Showcase during J.P. Morgan Week.
At this point, personalized cancer therapies are used to treat fourth- and fifth-line refractory patients, but by the time a therapy is manufactured, many of those patients will have died. That may not be the case with earlier-stage patients. As an added hurdle, Its difficult to control quality with point-of-care manufacturing.
The financial resources arent there for every patient to have personalized cancer therapy, Kanya Rajangam, M.D., Ph.D., CMO of Nkarta Therapeutics, emphasized. Thats why Nkarta and others are focusing upon therapeutics for broader populations.
That realization is driving precision medicine, in which companies like Nkarta and I-Mab Biopharma identify genetic common denominators that can benefit broader populations and lower treatment costs.
Thoughts around combination therapies are changing, too. Part of the challenge with this approach lies in defining the term effectiveness, Weimin Tang, chief business officer at I-Mab Biopharma said. Is it defined as generating a signal (against a target) or improving outcome?
Initially, researchers identified compounds with some degree of action against the target and combined them to create synergies. Now, in a stunning rethinking of the challenge, scientists are investigating compounds that have little or no effect as monotherapies but, when combined, generate promising signals.
Looking at a drugs isolated effects and whether those activities are statistically significant is an inefficient and unethical way to treat patients, particularly during a pandemic, Spiro Rombotis,president & CEO of Cyclacel Pharmaceuticals, said. He advised determining whether it makes biological and medical sense to combine particular therapies, with the understanding that some therapeutics that do not work well alone will work in combination.
Treatments for big bulk tumors are an example. As single monotherapies, few agents do much against big bulk solid tumors, he said. Building upon their synergies, however, one plus one can equal five. There are ways to combine therapeutics to enhance synergy.
Cell therapies also are emerging as potentially effective treatments, amidst the challenges of references that are framed in terms of complete response rates and durability of the therapeutic cell. Yet, complete response rates are irrelevant if the cancer cells werent completely obliterated, and durability doesnt matter since treatments have evolved from autologous to allogeneic and are administered over time.
Therefore, Ho said his major benchmark is when those who should be dead are still walking. Investors continue looking in terms of complete responses, but in cell therapy, I have a target and I either killed it or I didnt. If I didnt, its still growing. The patient may still die without any prolongation of life. We dont want to win the battle but lose the war.
In8bio is looking at gamma delta T cells to help solve that dilemma. Theyre unique and can be delivered allogeneically, and can distinguish between healthy cells and tumor cells, Ho said. We are seeing long-term responses beyond 17 and 20 months, depending on the program, and plan to announce data on our solid tumor program throughout the year.
The challenge, Ho explained, is not to go head-to-head with chemotherapy or any other treatment, but to drive a deeper response. If I eradicate the tumor, I dont need persistence of the cell. Our goal is to add to the standard of care to eliminate the cancer stem cells that remain and that ultimately grow back. Consequently, benchmarks for cell therapy should vary based upon the type of cancer, the trial population, the disease and patients prior treatments.
IO therapies also are looking at new targets. Theres a whole field of proteins associated with the progression of cancer, Rombotis pointed out, so protein degradation is garnering interest. Cyclacel, for example, is working to overcome cancers defenses by suppressing certain proteins, such as MCL,1 MYCN, MYC, MYB, BCL2A1 and MDM2. It expects to announce Phase I data from its oral, protein degradation program this year.
There very likely will be dozens of companies this year announcing Phase I data from protein degradation programs, he predicted. The field of overcoming resistance is very hot.
Despite these and other advancements, the overall pace of innovation has slowed and many me-too solutions are in development, panelists said. For example, more than 1,700 trials involving checkpoint inhibitors are active, enrolling by invitation, recruiting or not-yet recruiting, according to ClinicalTrials.gov.
From an investment perspective, The world is simple, moderator Kevin DeGeeter, managing director of healthcare research, at Oppenheimer & Co. Inc., concluded. In a bull market, investors embrace long-term value. In dreadful markets like we have currently, investors have a hard time looking beyond their noses.
Currently, Investors are focused on narrow silos, Ho added, but the biology is so complex that many of the elements are interlinked. The way to drive efficacy is to drive synergy through therapeutic combinations and new modalities to drive a broader response than existing therapeutics can deliver.
The challenge for biotech companies, DeGeeter stressed, isnt which therapy to develop, but whether they can generate results in a timeframe that investors can understand. Asking them to wait three years for data is a tough ask.
See original here:
- Registration is open for the ISSCR 2022 Annual Meeting 15-18 June - EurekAlert - January 13th, 2022
- Stem cell: UC's odd 'unmention' in its top 10 research tales - Capitol Weekly - January 13th, 2022
- Bone Marrow-Derived Stem Cells (BMSCS) Market Size Is Expected To Generate Huge Revenue and Competitive Outlook Industrial IT - Industrial IT - January 13th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 13th, 2022
- Legendary Bayer is Reinventing its Story with Cell and Gene Therapy - BioSpace - January 13th, 2022
- New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease after Stem Cell Transplantation - Newswise - January 11th, 2022
- Rising Focus on Exploring Potential of Stem Cells as Therapeutic Tools in Drug Targeting and Regenerative Medicine to Fuel Revenue Growth of Stem... - January 11th, 2022
- Stem Cell Media Market Statistics Based on Facts and Figures, 2022 to 2031 - Taiwan News - January 11th, 2022
- Regenerative Medicine: Innovation & Innovators leading online scientific event by IASRM in this pandemic - ThePrint - January 11th, 2022
- JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies - BioPharma Dive - January 11th, 2022
- Severe Combined Immunodeficiency Treatment Market: Availability of Drugs and Immune-related Treatments Are Anticipated to Drive the Global Market -... - January 11th, 2022
- Peter Dirks, Asthma and Physics - Brain Tumour Research - January 9th, 2022
- Overview - Brain Tumor Stem Cell Research Lab - Mayo ... - January 7th, 2022
- Religious Groups Official Positions on Stem Cell Research ... - January 7th, 2022
- EBMT trial demonstrates improvements in immunosuppressive treatment of patients with Severe Aplastic Anemia - EurekAlert - January 7th, 2022
- CMML vs. CML: What's the Difference? - Healthline - January 7th, 2022
- Effects of Stem Cell Therapy on Diabetic Mellitus Erectile Dysfunction: A Systematic Review and Meta-analysis - Newswise - January 5th, 2022
- Researchers Awarded Grant to Study New Method of Islet Transplantation - Weill Cornell Medicine Newsroom - January 5th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Adenovirus (AdV) Infections in... - January 5th, 2022
- Jake's mice: Searching for answers to the puzzle of autism - huntingdondailynews.com - January 5th, 2022
- Freeze Thaw Chambers Market: The cryopreserved products segment is expected to drive the growth of the market - BioSpace - January 5th, 2022
- Gait Rehabilitation System Market: Rising incidence of various neurological disorders to drive the market - BioSpace - January 5th, 2022
- Worldwide Translational Regenerative Medicine Industry to 2026 - Ongoing Research in Organ Transplantation With Regenerative Medicine Presents... - January 5th, 2022
- These 2021 Biotech Breakthroughs Will Shape the Future of Health and Medicine - Singularity Hub - January 5th, 2022
- LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies - Yahoo Finance - January 2nd, 2022
- Dental mesenchymal stromal/stem cells in different microenvironments implications in regenerative therapy - Newswise - January 2nd, 2022
- Bristol Myers Squibb exec on the companys growth in Seattle and beating cancer with immune cells - GeekWire - January 2nd, 2022
- Postdoc Position in Bioinformatics in Stem Cell Neurobiology job with MASARYK UNIVERSITY | 276195 - Times Higher Education (THE) - December 25th, 2021
- USC Stem Cell - December 25th, 2021
- Communication between cells plays a major role in deciding their fate - EurekAlert - December 25th, 2021
- Researchers uncover new details behind inflammation that promotes heart disease - EurekAlert - December 25th, 2021
- Epithelial Cell Culture Media Market to hit US$ 303040.33 thousand by 2028, at 11.4% CAGR: The Insight Partners - Digital Journal - December 25th, 2021
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Communication between cells plays a major role in deciding their fate > News > USC Dornsife - USC Dornsife College of Letters, Arts and Sciences - December 23rd, 2021
- Emendo Biotherapeutics and Seattle Childrens Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 23rd, 2021
- The 10 Most Compelling Research Stories of 2021 PharmaLive - PharmaLive - December 23rd, 2021
- UTSW working to reprogram cells to strengthen immunity in geriatric patients - EurekAlert - December 23rd, 2021
- Cell Proliferation Kit Market Objectives of the Study Includes Research Methodology and Assumptions and Forecast by 2031 - Digital Journal - December 23rd, 2021
- Drexel Researchers Develop and Employ Cell-Based Approach to Studying Mechanisms of Gulf War Illness - Drexel News Blog - December 21st, 2021
- This Startup Is Makingand ProgrammingHuman Cells - WIRED - December 21st, 2021
- Amniotics joins Vinnova funded 'CAMP' to improve outcome of lung transplantations with PulmoStem - marketscreener.com - December 21st, 2021
- COVID-19: Are T cell vaccines the future? - Medical News Today - December 21st, 2021
- The 10 Most Compelling Research Stories of 2021 - BioSpace - December 21st, 2021
- SpaceX CRS-24 launching multiple life science investigations to the International Space Station - EurekAlert - December 21st, 2021
- Fast food: Israeli team stumbles upon speed boost for slow-growing cultured meat - The Times of Israel - December 21st, 2021
- MRC Lead Apologizes Following Bullying Allegations - The Scientist - December 21st, 2021
- End of Year Wrap Up: Key Updates in Myeloma in 2021 and Possible Upcoming FDA Updates - Cancer Network - December 21st, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 17th, 2021
- IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing... - December 17th, 2021
- Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology ... - The Bakersfield Californian - December 17th, 2021
- Outlook on the Cell Isolation Global Market to 2026 - by Technique, Cell Type, Product, Application, End-use and Region - ResearchAndMarkets.com -... - December 17th, 2021
- CAR T-cell Therapy Found Equivalent to Standard of Care as Second-line Treatment for Aggressive non-Hodgkin Lymphoma - PRNewswire - December 15th, 2021
- Novel CD19-Directed CAR T-Cell Therapy Shows Favorable Results in R/R DLBCL - Targeted Oncology - December 15th, 2021
- Global CRISPR Technology Market Research Report 2021: Focus on Design Tools, Plasmid and Vector, Cas9 and G-RNA, & Delivery System Products -... - December 15th, 2021
- Building an entrepreneurial ecosystem is about a lot more than education and science funding - American Enterprise Institute - December 15th, 2021
- Q&A: Dr. Thomas Rando on preventing age-related diseases and turning discoveries into cures - UCLA Newsroom - December 12th, 2021
- Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology... - December 12th, 2021
- Ten Problems with Embryonic Stem Cell Research | The ... - December 11th, 2021
- New stem cell identified for lung tissue regeneration ... - December 11th, 2021
- Harvard Department of Stem Cell and Regenerative Biology ... - December 11th, 2021
- Stem Cells Australia | Australian research, stem cell ... - December 11th, 2021
- Research Assistant Stem Cell Project Job at The Florey Institute in Melbourne, Australia - The Conversation AU - December 11th, 2021
- Ethical issues cloud case report of unproven stem cell therapy for autism - Spectrum - December 11th, 2021
- Mesenchymal Stem Cells Market Size 2021 Emerging Technologies, Global Regions with Industry Share Analysis, Gross Margin, Regional Demand and Forecast... - December 11th, 2021
- For children, young adults with recurrent AML, immunotherapy shows promise Washington University School of Medicine in St. Louis - Washington... - December 11th, 2021
- UEA researchers reveal how immune cells use the bodys fat stores to fight infection - News-Medical.net - December 11th, 2021
- Sanford Health opens study of cell injections for arthritis - Sanford Health News - December 11th, 2021
- Cell types outside the pancreas make insulin, too, study shows - Yale News - December 11th, 2021
- Doctoral Student Finds Alternative Cell Option For Organs-On-Chips - Texas A&M University Today - December 11th, 2021
- Caring Cross Announces Publication in Nature Communications Demonstrating Effectiveness of Place-of-Care Manufacture of Anti-CD19 CAR T Cells for... - December 11th, 2021
- Stem cells and the future of health care - The Globe and Mail - December 9th, 2021
- How the body uses fat to fight infection - EurekAlert - December 9th, 2021
- The Ethics of Human Cloning and Stem Cell Research ... - December 7th, 2021
- An Overview of Stem Cell Research | The Center for ... - December 7th, 2021
- Global Research Antibodies Outlook to 2028: Rise in R&D Initiatives and an Increase in Neurobiology and Stem Cell Research are Key Factors in Market... - December 7th, 2021
- University of Michigan Stem Cell Research | Frequently ... - November 30th, 2021
- Postdoctoral Research Associate in Centre for Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 273388 - Times Higher Education... - November 30th, 2021
- Stem cell therapy potentially could treat Type 1 diabetes by helping patients produce insulin - USA TODAY - November 30th, 2021
- UCLA Broad Stem Cell Research Center receives $5 million ... - November 30th, 2021
- ReproCELL Incorporated : Everything you need to know about the REPROCELL iPSC Biobank - marketscreener.com - November 30th, 2021